The Death of Arcoxia: Drug Regulation in a "Whistleblower" Climate
This article was originally published in RPM Report
Executive Summary
There may not be a worse time to push a new drug through FDA-especially a "me-too" product with a questionable benefit-risk profile. Until Congress releases its grasp on the approval process, FDA isn't taking any chances. Unfortunately for industry, a few drugs are getting caught in the crossfire. Merck seemed unprepared for the new climate with Arcoxia; will other sponsors learn the lesson?
You may also be interested in...
The FDA Roundtable Part I: The Regulators' View of Drug Development
Three top FDA officials sat down with The RPM Report at their White Oak campus to discuss the top drug regulatory issues. On the table for discussion: drug safety, comparative effectiveness and the future of drug development.
The FDA Roundtable Part I: The Regulators' View of Drug Development
Three top FDA officials sat down with The RPM Report at their White Oak campus to discuss the top drug regulatory issues. On the table for discussion: drug safety, comparative effectiveness and the future of drug development.
Separate But Equal: FDA Reaffirms Drug Safety Role in Approval Process
There's a new drug safety structure at FDA, with the Office of Surveillance & Epidemiology gaining greater influence in how the agency manages things like REMS and product withdrawals. In many ways, it's a codification of an existing relationship between safety and review officials. But some sponsors worry it will also result in a less friendly approval process.